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Severe hypercalcemia as a form of acute 
lymphoblastic leukemia presentation in children
CASE REPORT
INTRODUCTION
Hypercalcemia is an uncommon metabolic disorder in children. The 
differential diagnosis is complex and varies with age at presentation. Metabolic, 
nutritional, drug-induced, genetic, inflammatory and neoplastic factors may 
also be involved.(1)
Although common in adults, malignancy-associated hypercalcemia (MAH) 
is a rare complication at pediatric age and occurs in 0.4 to 1.3% of cancers, of 
which acute lymphoblastic leukemia is the most common in this age group.(2,3)
Treatment of MAH consists in the treatment of the underlying malignancy. 
In severe and persistent hypercalcemia, the initial approach is hyperhydration.(4) 
As a part of standard treatment, prednisolone is effective in cases of moderate 
severity.(4) Calcitonin is often reported as a treatment for pediatric MAH but has 
a modest hypocalcemic effect and is not marketed in Portugal. Bisphosphonates 
have been extensively studied and are effective in adult MAH. However, due 
to the rarity of the disease in children and the potential adverse effects with 
respect to osteogenesis, studies of efficacy and safety in this age group are 
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Hypercalcemia is a rare metabolic 
disorder in children and is potentially 
fatal. It has a wide differential diagnosis, 
including cancer. Here, we report the case 
of a previously healthy 3-year-old who 
was admitted to the emergency room 
with fatigue, hyporeactivity, fever and 
limping gait that had evolved over 5 days 
and that was progressively worsening. On 
examination the patient was unconscious 
(Glasgow coma score: 8). Laboratory 
tests indicated severe hypercalcemia 
(total calcium 21.39mg/dL, ionized 
calcium 2.93mmol/L) and microcytic 
anemia. Hyperhydration was initiated, 
and the child was transferred to the 
pediatric intensive care unit. Continuous 
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Hipercalcemia grave como forma de apresentação de leucemia 
linfoblástica aguda em crianças
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venovenous hemodiafiltration with 
calcium-free solution was instituted, 
which brought progressive normalization 
of serum calcium and an improved 
state of consciousness. Zoledronate 
was administered, and metabolic 
and infectious causes and poisoning 
were excluded. The bone marrow 
smear revealed a diagnosis of acute 
lymphoblastic leukemia. Hypercalcemia 
associated with malignancy in children 
is rare and occurs as a form of cancer 
presentation or recurrence. Continuous 
venovenous hemodiafiltration should be 
considered in situations where there is 
imminent risk to life.
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limited.(4) Nonetheless, small case series have confirmed its 
effectiveness.(5) Severe symptomatic hypercalcemia requires 
emergency correction with continuous venovenous 
hemodiafiltration.
CASE REPORT
A 3-year-old male child weighting 16kg with 
unremarkable past medical history presented with tiredness 
that had evolved over 1 week. Five days before admission, 
he started fever, left coxalgia and limping gait in the context 
of recent trauma. Due to symptom maintenance, the child 
was re-evaluated 3 days before admission. Imaging and 
laboratory studies did not suggest osteoarticular infection, 
and the child was given symptomatic treatment. Since 
the clinical picture persisted and was, accompanied by 
prostration, hyporeactivity and refusal to eat, he returned 
to the emergency room.
On admission, the patient was unconscious (Glasgow 
coma score: 8) with the maintenance of osteotendinous 
reflexes. He was hemodynamically stable and did not 
present any other alterations, such as rash, blood dyscrasia, 
lymphadenopathy, hepatomegaly or splenomegaly.
Laboratory evaluation revealed compensated 
metabolic alkalosis (pH of 7.41, partial pressure of 
carbon dioxide [PaCO2] of 48.7mmHg, bicarbonate 
[HCO3] of 32.5mmol/L and base excess of 9.6) and 
severe hypercalcemia (total calcium 21.8mg/dL, ionized 
calcium 2.93mmol/L). Other evaluations are shown 
in table 1. Craniocephalic computed tomography and 
renal, abdominal and hip joint ultrasound showed no 
significant changes.
Given the clinical and laboratory severity of 
hypercalcemia, on suspicion of osteoarticular infection, 
intravenous hyperhydration was initiated (2,500mL/
m2/day), and antibiotics were given (flucloxacillin 
and gentamicin). The child was transferred to the 
pediatric intensive care unit. Continuous venovenous 
hemodiafiltration was initiated after a 6.5F hemodialysis 
central venous catheter was placed in the right femoral 
vein. An HF20 filter was used and priming was performed 
with 5,000 UI of heparin in 1L of 0.9% sodium 
chloride. Continuous venovenous hemodiafiltration was 
programmed in accordance with the pediatric protocol (25 
- 40mL/kg/h = 1/3 dialysis fluid + 2/3 fluid replacement 
(2/3 prefilter + 1/3 post-filter)). Ultrafiltrate was calculated 
according to the desired fluid balance.(6) A replacement 
and calcium-free dialysis solution was used (Prism0Cal®, 
Gambro - Lund, Sweden). Regional anticoagulation was 
Table 1 - Evaluation performed on admission
Analysis Result Reference value
Hemoglobin (g/dL) 9.3 11.5 - 11.5
Hematocrit (%) 26.6 34 - 43
Mean corpuscular volume (fL) 73.1 75 - 90
Leukocytes (/uL) 5,500 4,000 - 12,000
Neutrophils (/uL) 2,300
Lymphocytes (/uL) 2,500
Platelets (/uL) 186,000 150,000 - 350,000
C-reactive protein (mg/dL) 7.96 < 0.3
Urea (mg/dL) 60 17 - 38.5
Creatinine (mg/dL) 0.83 0.5 - 1.1
Albumin (g/dL) 3.3 3.6 - 5.2
Aspartate aminotransferase (UI/L) 42 10 - 47
Alanine aminotransferase (UI/L) 48 24 - 49
Lactate dehydrogenase (UI/L) 739 155 - 280
Alkaline phosphate (UI/L) 121 191 - 450
Serum inorganic phosphorus (mg/dL) 3.1 4.0 - 6.0
Serum magnesium (mg/dL) 1.1 1.7 - 2.4
Serum potassium (mmol/L) 2.52 3.5 - 5.0
Serum sodium (mmol/L) 133 135 - 145
performed with machine-perfused unfractionated heparin, 
the dose of which was adjusted according to the patient’s 
activated partial thromboplastin time. The technique 
was maintained for 72 hours and took place without 
complications. As a therapeutic supplement, intravenous 
zoledronate (0.025mg/kg) was administered on the third 
day of hospitalization. There was a progressive decrease in 
total and ionized calcium levels and an improved state of 
consciousness (Figure 1).
The investigation revealed low (unmeasurable) serum 
intact parathyroid hormone (PTH) and excluded metabolic 
and infectious causes and vitamin or drug poisoning 
(Table 2). Skeletal radiography excluded osteolytic lesions.
During hospitalization, progressive pancytopenia 
(hemoglobin 7.7g/dL, leukocytes 2200/uL, platelets 
67000/uL) was identified and bone marrow examination 
was performed, which confirmed precursor B-cell acute 
lymphoblastic leukemia.
After diagnosis, the child was transferred to a pediatric 
oncology referral center, where, after further review, 
remission induction therapy was started (2005 ALL-DFCI 
protocol of the Dana-Farber Cancer Institute). The 
complementary evaluation by flow cytometry revealed 69% 
infiltration of B lymphoblasts. During hospitalization, there 
were periods of asymptomatic hypocalcemia (minimum 
404 Martins AL, Moniz M, Nunes PS, Abadesso C, Loureiro HC, Duarte X, et al.
Rev Bras Ter Intensiva. 2015;27(4):402-405
Table 2 - Laboratory tests performed
Analysis Result Reference value
PTH intact < 20
PTHrp (pmol/L) 1.2 < 2.0
1.25 (OH)2D (pmol/L) 2 39 - 193
25 (OH)D (ng/dL) 12.7 30 - 100
Retinol (ng/dL) 21 30 - 70
ACE (U/L) 20.10 12 - 68
EBV-VCA IgM/IgG Negative/positive
Parvovirus B19 IgM/IgG Negative/positive
CMV IgM/IgG Negative/positive
Mycoplasma pneumoniae IgM/IgG Negative/negative
HIV 1/2 Negative
FT3 (pg/mL) 2.31 4.0 - 7.10
FT4 (ng/dL) 0.56 0.9 -1.70
TSH (mUI/L) 0.496 0.8 - 7.5
Total proteins (g/dL) 5.6 6 - 8
Albumin (g/dL) 2.53 3.75 - 5.01
Uric acid (mg/dL) 9.4 3.0 - 5.5
PTH - parathyroid hormone; PTHrp - parathyroid hormone-related protein; 1.25 (OH)2D 
- 1.25-dihydroxy-vitamin D; 25(OH)D - Vitamin D in the form of 25-hydroxyvitamin D; 
ACE - angiotensin converting enzyme; EBV-VCA - viral capsid antigen of the Epstein-Barr 
virus; CMV - cytomegalovirus; HIV - human immunodeficiency virus; FT3 - free T3 hormone; 
FT4 - free T4 hormone; TSH - thyroid stimulating hormone.
5.9mg/dL at day 10 post-zoledronate), which required 
intravenous correction. A bone marrow smear performed 4 
weeks after the beginning of induction therapy confirmed 
complete remission both morphologically and by molecular 
biology.
Currently, approximately 10 months after starting 
treatment, the child remains in remission.
DISCUSSION
Hypercalcemia is a potentially fatal disorder, regarding 
its neurological and cardiac complications. The treatment 
includes hyperhydration, bisphosphonates and treatment 
of the underlying disease.(1) Occasionally, rapid correction 
of the disturbance becomes crucial, particularly in the 
setting of loss of consciousness or when the hypercalcemia 
is refractory to conventional measures. In such situations, 
the use of continuous venovenous hemodiafiltration has 
been identified as an effective treatment.(7,8) Its successful 
use in severe hypercalcemia has been reported in adults,(8-11) 
but the use of the technique in pediatrics has rarely been 
described in the literature.(7,12) In this case report, due to 
severe hypercalcemia on admission, the use of dialysis 
solution with calcium-free replacement was chosen. Regular 
analytical calcemia controls were performed in order to 
avoid a sudden decrease and below-normal values. The renal 
replacement therapy settings were set in order to provide 
a gradual decrease in serum calcium, thereby avoiding 
complications such as circuit clotting. As the patient did 
not present spontaneous diuresis, it was decided to program 
losses to ensure a neutral fluid balance. Following clinical 
and laboratory stabilization, zoledronate was introduced 
to maintain normocalcemia, as the effect of continuous 
venovenous hemodiafiltration is temporary.(11) Continuous 
monitoring of serum calcium levels was assured due to the 
risk of hypocalcemia observed in this case.(13)
The etiological investigation suggested an independent 
PTH mechanism. Metabolic and infectious causes and 
vitamin or drug poisoning were excluded. Progressive 
pancytopenia led to the suspicion of MAH, which 
ultimately led to the final diagnosis.
Figure 1 - Evolution of total calcemia during hospitalization in the pediatric intensive care unit. Grey area: total calcium reference value limits; black bars: period under continuous venovenous 
hemodiafiltration; grey bars: period under calcium supplementation. IPO - Instituto Português de Oncologia.
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The pathogenesis of MAH includes the stimulation 
of bone resorption, mediated by proteins and cytokines 
produced by the tumor cells or by the tumoral 
microenvironment. Two distinct mechanisms are 
described, which include hypercalcemia by local osteolytic 
lesions (bone metastasis) and humoral hypercalcemia by 
the activation of RANK-RANKL (receptor activator of 
nuclear factor κB and its ligand). Parathyroid hormone-
related protein (PTHrP) is the most frequently involved 
mediator, but other mediators, such as interleukin (IL)-1, 
IL-6, tumor necrosis factor alpha (TNF-α), transforming 
growth factor beta (TGF-β), prostaglandins and even 
calcitriol and ectopic PTH production may be involved.(4)
In acute lymphoblastic leukemia, an association with 
hypercalcemia in patients with t (17;19) has been reported, 
suggesting the possible induction of PTHrP.(3,14) In this 
case, this cytogenetic abnormality was not observed, and 
high levels of PTHrP were not detected, thus excluding 
this mechanism as the primum movens of hypercalcemia.
CONCLUSION
The described case shows an infrequent complication, 
not only at pediatric age, but also in children with oncological 
diseases, suggesting that this metabolic emergency unveils 
of the underlying disease. Continuous venovenous 
hemodiafiltration with calcium-free solution as a first-line 
treatment in cases of severe and symptomatic hypercalcemia 
was found to be effective in the rapid induction of 
normocalcemia and neurological improvement, buying 
valuable time until maintenance treatment focused on the 
etiology can exert a sustained effect.
A hipercalcemia é um distúrbio metabólico raro em pediatria, 
potencialmente fatal, apresentando um vasto diagnóstico 
diferencial, incluindo neoplasias. Relatamos aqui o caso de uma 
criança de 3 anos, previamente saudável, admitida no serviço 
de urgência por fadiga, hiporreatividade, febre e claudicação da 
marcha com 5 dias de evolução, de agravamento progressivo. 
À observação, apresentava-se inconsciente (escore de coma 
Glasgow: 8). Laboratorialmente, apresentava hipercalcemia 
grave (cálcio total 21,39mg/dL, ionizado 2,93mmol/L) e 
anemia microcítica. Iniciou hiper-hidratação e foi transferido 
para a unidade de cuidados intensivos pediátricos. Instituiu-se 
hemodiafiltração venovenosa contínua com soluto livre de 
cálcio, ocorrendo a progressiva normalização da calcemia, 
com melhoria do estado de consciência. Administrou-se 
zolendronato. Excluíram-se causas metabólicas, infecciosas e 
intoxicação. O mielograma permitiu o diagnóstico de leucemia 
linfoblástica aguda. A hipercalcemia associada à malignidade 
em pediatria é rara, ocorrendo como forma de apresentação da 
neoplasia ou na recorrência desta. Em situações com risco de 
vida iminente, deve se considerar hemodiafiltração venovenosa 
contínua.
RESUMO
Descritores: Hipercalcemia; Leucemia-linfoma linfoblástico 
de células T precursoras; Hemodiafiltração; Relatos de casos
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